Liquid Biopsy in Lung Cancer: A Perspective From Members of the Pulmonary Pathology Society

摘要: Liquid biopsy has received extensive media coverage and been called the holy grail of cancer detection. Attempts at circulating tumor cell genetic material capture have progressing for several years, recent financially technically feasible improvements devices, plasma isolation techniques, highly sensitive polymerase chain reaction- sequencing-based methods advanced possibility liquid solid tumors. Although practical use RNA-based testing hindered by need to fractionate blood enrich RNAs, detection cells profited from advances in technology. In fact, US Food Drug Administration approved one selection platform, CellSearch System. a patient population with genomically defined may potentially be clinically useful, it currently does not supersede conventional pretreatment tissue diagnosis lung cancer. validated diagnosis, its lower sensitivity could lead significant diagnostic delay if were used lieu biopsy. Ultimately, notwithstanding enthusiasm encompassing biopsy, clinical utility remains unproven.